Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracinostat + azacitidine vs placebo + azacitidine in AML unfit for intensive chemotherapy
CTR20191971Phase 3Terminated
- Sponsor
- Helsinn
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pracinostat in acute myeloid leukemia (AML), sponsored by Helsinn. Started Dec 2019; status: terminated.
02
Drugs
pracinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20191971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191971.